Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment.

21 April 2026

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones.

21 April 2026

Biotechnology·NYSE:LLY·Pharmaceuticals

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer picked up a new short-term catalyst Monday, with the U.S. Food and Drug Administration handing a priority review to its Padcev submission for bladder cancer. The stock gained roughly 0.8%, trading at $27.78 in the afternoon, drawing renewed attention as the company pushes ahead with a wider pipeline.

20 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson topped Wall Street’s Q1 expectations on Tuesday, helped by surging sales from the cancer therapy Darzalex and the psoriasis drug Tremfya. Those gains made up for a sharp decline in Stelara, which used to be a major driver. Revenue climbed 9.9% to $24.1 billion, beating forecasts of $23.6 billion. Adjusted earnings reached $2.70 a share, also above the $2.66 consensus. The company lifted its 2026 outlook.

14 April 2026

Earnings·NYSE:JNJ·Pharmaceuticals·Stock Market

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics yanked its European application for VIOKAT on Tuesday, just a day after striking a $2.9 billion cash deal to be acquired by Neurocrine Biosciences. That move halts a regulatory review Soleno had earlier projected might wrap up by mid-2026.

7 April 2026

Biotechnology·NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences is set to buy Soleno Therapeutics Inc. in a $2.9 billion all-cash transaction announced Monday, offering $53 per share to Soleno holders. Shares of the rare-disease specialist traded at $52.25, just shy of the bid.

7 April 2026

NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals·Stock Market

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Between April 3 and April 6, a trio of reports drawing on fourth-quarter 13F filings detailed that Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners each cut back on Pfizer positions—together unloading 740,174 shares. On Monday, Pfizer stock slipped roughly 0.7% to $28.12 in U.S. trading.

6 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Shares of Apellis Pharmaceuticals hovered close to Biogen’s $41-per-share bid on Wednesday, following news of the $5.6 billion cash-and-contingent deal announced a day earlier. The stock last traded at $40.23 in the U.S. session.

1 April 2026

NASDAQ:APLS·NASDAQ:BIIB·Pharmaceuticals·Stock Market

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer hit a new 52-week high Tuesday, lifted by upbeat analyst notes and a string of pipeline news fueling demand. Shares last changed hands at $27.87 late in the morning, having reached $28.30 earlier—eclipsing the earlier high-water mark of $27.92.

31 March 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly kicks off the week with a fresh pipeline pact in hand. Insilico Medicine on Sunday announced it struck a global licensing and research deal with the U.S. pharma giant, a tie-up valued at as much as $2.75 billion. Lilly shares finished Friday at $878.24, off 2.1%. The stock sits more than 22% beneath its Jan. 8 peak.

29 March 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals ended Friday down 4.6% at $433.07, reacting to fresh U.S. safety label updates for its flagship cystic fibrosis therapies. Despite the pressure from the label news, BMO Capital’s Evan David Seigerman stood by his outperform call and kept the price target at $600.

28 March 2026

NASDAQ:VRTX·Pharmaceuticals·Stock Market

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

In U.S. premarket action Thursday, Terns Pharmaceuticals was pegged at $52.86, matching Wednesday’s close and sitting roughly 14 cents under Merck’s $6.7 billion all-cash bid for the biotech. Terns had surged 5.8% by the end of Wednesday’s session.

26 March 2026

NASDAQ:TERN·NYSE:MRK·Pharmaceuticals·Stock Market

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion cash deal, offering $53 per share, the companies said Wednesday. The move hands Merck an experimental leukemia drug and underlines its push into oncology. The announcement followed a Financial Times report earlier in the day that discussions were already advanced.

25 March 2026

NASDAQ:TERN·NYSE:MRK·Pharmaceuticals

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk slipped 1.5% to 237.90 Danish crowns in Copenhagen on Thursday, despite the FDA signing off on a higher-dose Wegovy injection. The stock remained in the red after Eli Lilly unveiled new obesity drug results, and as Reuters flagged that semaglutide patent expiry in India could clear the way for lower-cost generics of the compound found in both Wegovy and Ozempic.

20 March 2026

CSE:NOVO.B·Pharmaceuticals·Stock Market

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.

19 March 2026

Health News·NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Inc. slipped about 1% to close at $26.60 on Friday, landing near the session’s low as investors digested fresh developments in the respiratory syncytial virus vaccine landscape and a boost for blood thinner Eliquis. The pressure came after GSK announced the FDA had expanded Arexvy’s approval to include at-risk adults 18 to 49. Meanwhile, separate results highlighted strong outcomes for Eliquis in treating serious blood clots.

13 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer ended Thursday down 1.6% at $26.86, caught up in a sweeping selloff across U.S. equities. Oil prices jumped on intensifying Middle East tensions, and the slide hit all three major indexes—S&P 500, Dow, and Nasdaq—each losing over 1.5%.

12 March 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst

Pfizer slipped roughly 0.4% to $27.05 midday Wednesday in New York. Investors reacted after the Washington Post said U.S. vaccine advisers scrapped plans to scrutinize mRNA COVID vaccines, removing a potential regulatory obstacle for the company’s vaccine segment.

11 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent

Pfizer’s experimental eczema treatment, tilrekimig, hit its main target in a mid-stage trial, the company said Monday. That outcome sets up a late-stage study slated for later this year, pushing Pfizer nearer to a market still dominated by Sanofi and Regeneron’s Dupixent.

9 March 2026

NYSE:PFE·Pharmaceuticals

Previous 1 … 10 11 12 13 14 … 49 Next

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent

TechStock² Updates

Nasdaq pares loss to 1.1% amid heavy trading as oil shock rattles markets

Nasdaq Falls Twice as Fast as S&P 500 as 10-Year Yield Hits 4.79%

AEye Shares Surge 26% After Lunar Lidar Agreement Overshadows Quarterly Turnover

UiPath Shares Trade 29% Over Analyst Price Target Ahead of Earnings

Medtronic Shares Climb 3.2% Following Upgraded Outlook and $700 Million Investment in Robotics

Ambev ADR Rises 0.7% as Brazilian Beer Sales Support Margin Outlook

Nasdaq Futures Drop 1.35% as Crude Surpasses $92 and Bond Yields Climb

GoPro Surges 64% Premarket After $87 Million Debt Faces Markiplier-Led Rally

American Airlines Shares Dip 1.2% With $92 Oil Squeezing Earnings Margins

Nasdaq Futures Fall 1.2% as 10-Year Treasury Yield Approaches 4.8%

Investment Disclaimer